[{"orgOrder":0,"company":"Petrovax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Azoximer Bromide","moa":"polymers","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Petrovax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Petrovax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Petrovax \/ Undisclosed"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Russian Direct Investment Fund","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Russian Direct Investment Fund \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Russian Direct Investment Fund \/ Undisclosed"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Russian Direct Investment Fund","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Russian Direct Investment Fund \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Russian Direct Investment Fund \/ Undisclosed"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : Russian Direct Investment Fund (RDIF) and the ChemRar Group – will provide international partners with access to special preliminary clinical data for Avifavir, with detailed recommendations for usage of the drug.

                          Product Name : Avifavir

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 29, 2020

                          Lead Product(s) : Favipiravir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : Positive first interim results of the multicenter randomized open comparative clinical trial of the drug Favipiravir on patients hospitalized with COVID-19 were announced. 60% of the 40 patients who took Favipiravir have tested negative for Covid-19 afte...

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 13, 2020

                          Lead Product(s) : Favipiravir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : Azoximer Bromide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Coronavirus Infections.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 08, 2020

                          Lead Product(s) : Azoximer Bromide

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank